【AI Explained】Chimeric antigen receptor T cell therapy: 25years in the making.

Literature Information

TL;DR

This review discusses the evolution of chimeric antigen receptor (CAR) T cell therapy from a theoretical concept to a practical treatment for cancer, highlighting significant advancements in molecular biology and cell production that have facilitated its clinical application. The authors aim to provide insights and lessons from the initial years of CAR T cell therapy to inform clinicians and enhance patient care.

Search for more papers on MaltSci.com

Adoptive immunotherapy · Chimeric antigen receptor T cells

Abstract

Chimeric antigen receptor (CAR) T cell therapy of cancer is generating enormous enthusiasm. Twenty-five years after the concept was first proposed, major advances in molecular biology, virology, and good manufacturing practices (GMP)-grade cell production have transformed antibody-T cell chimeras from a scientific curiosity to a fact of life for academic cellular immunotherapy researchers and, increasingly, for patients. In this review, we explain the preclinical concept, outline how it has been translated to the clinic, and draw lessons from the first years of CAR T cell therapy for the practicing clinician.

MaltSci.com AI Research Service

Primary Questions Addressed

1. What are the key molecular biology advancements that have facilitated the development of CAR T cell therapy over the past 25 years?
2. How have good manufacturing practices (GMP) influenced the production and scalability of CAR T cell therapies?
3. What lessons have been learned from the initial clinical applications of CAR T cell therapy that can inform future research and practice?
4. In what ways have preclinical studies shaped the understanding and effectiveness of CAR T cell therapies in clinical settings?
5. How does the evolution of CAR T cell therapy impact the future landscape of cancer treatment and immunotherapy?

Key Findings

Key Insights: Chimeric Antigen Receptor T Cell Therapy: 25 Years in the Making

1. Research Background and Objective: The development of Chimeric Antigen Receptor (CAR) T cell therapy represents a significant milestone in cancer treatment, emerging from a conceptual framework established 25 years ago. The primary objective of this review is to provide a comprehensive overview of the evolution of CAR T cell therapy, highlighting the transformative advancements in molecular biology, virology, and the establishment of Good Manufacturing Practices (GMP) for cell production. By tracing the journey from a theoretical idea to a practical application in clinical settings, the review aims to equip practicing clinicians with insights and lessons learned from the initial years of CAR T therapy implementation.

2. Main Methods and Findings: The review outlines the preclinical foundations of CAR T cell therapy, detailing the mechanisms by which engineered T cells can target and eliminate cancer cells. It describes key advancements in technology that have enabled the production of CAR T cells, emphasizing the importance of GMP-grade manufacturing to ensure safety and efficacy. The authors present evidence from clinical trials that demonstrate the therapy’s success in treating various hematological malignancies, underscoring the response rates and durability of treatment outcomes. Additionally, the review reflects on the challenges faced during the translation from bench to bedside, including issues related to toxicity, persistence of CAR T cells, and the need for patient selection criteria.

3. Core Conclusion: The review concludes that CAR T cell therapy has transitioned from a scientific curiosity to a cornerstone of cancer immunotherapy, with tangible benefits observed in patients. The lessons learned over the past 25 years highlight the critical role of interdisciplinary collaboration among researchers, clinicians, and regulatory bodies in advancing this field. Moreover, the review emphasizes the need for ongoing research to address current limitations and optimize therapeutic strategies for broader patient populations.

4. Research Significance and Impact: The significance of this research lies in its potential to reshape cancer treatment paradigms, offering hope to patients with previously untreatable malignancies. The advancements in CAR T therapy not only enhance patient outcomes but also pave the way for future innovations in cellular therapies. The insights provided in this review serve as a valuable resource for clinicians, fostering a better understanding of CAR T cell therapy’s complexities and encouraging the integration of new findings into clinical practice. Ultimately, the continued evolution of CAR T therapy will contribute to the broader field of personalized medicine, enhancing the ability to tailor treatments to individual patient needs and improving overall survival rates in cancer care.

Literatures Citing This Work

1. T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies. - Nasheed M Hossain;Aude G Chapuis;Roland B Walter - Current hematologic malignancy reports (2016)
2. Chimeric antigen receptor T-cell therapy for solid tumors. - Kheng Newick;Edmund Moon;Steven M Albelda - Molecular therapy oncolytics (2016)
3. Clinical manufacturing of CAR T cells: foundation of a promising therapy. - Xiuyan Wang;Isabelle Rivière - Molecular therapy oncolytics (2016)
4. Driving an improved CAR for cancer immunotherapy. - Xiaopei Huang;Yiping Yang - The Journal of clinical investigation (2016)
5. Current status of engineered T-cell therapy for synovial sarcoma. - Matthew Dallos;William D Tap;Sandra P D’Angelo - Immunotherapy (2016)
6. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. - Zulmarie Perez Horta;Jacob L Goldberg;Paul M Sondel - Immunotherapy (2016)
7. Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors. - Robert Moot;Sunil S Raikar;Lauren Fleischer;Melissa Querrey;Daniel E Tylawsky;Hirotomo Nakahara;Christopher B Doering;H Trent Spencer - Molecular therapy oncolytics (2016)
8. Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? - Valérie Dutoit;Denis Migliorini;Pierre-Yves Dietrich;Paul R Walker - Frontiers in oncology (2016)
9. Masked Chimeric Antigen Receptor for Tumor-Specific Activation. - Xiaolu Han;Paul D Bryson;Yifan Zhao;Gunce E Cinay;Si Li;Yunfei Guo;Natnaree Siriwon;Pin Wang - Molecular therapy : the journal of the American Society of Gene Therapy (2017)
10. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. - Elizabeth S Allen;David F Stroncek;Jiaqiang Ren;Anne F Eder;Kamille A West;Terry J Fry;Daniel W Lee;Crystal L Mackall;Cathy Conry-Cantilena - Transfusion (2017)

… (105 more literatures)

© 2025 MaltSci - We reshape scientific research with AI technology